Reports
Pathways for Chinese pharmaceutical companies to enter EU markets
China was significantly behind the European Union (EU) in starting to approve biosimilars/copy biologicals. However, despite the small number of copy biologicals approved in the country, China has been much faster to commercialize such products [1].
Chinese biosimilars (copy biological) in European markets
A presentation entitled ‘International commercialization on biosimilars’ delivered by Dr Jenny Hao of Convergence in November 2021 at the Festival of Biologics meeting in Basel, Switzerland discussed the challenges and opportunities for Chinese biosimilar (copy biological) companies to market their products in the European Union.
Preparing for future biosimilar opportunities
Fifty-five per cent of biosimilar opportunities from loss of exclusivity come from just 10% (13) biologicals, which are concentrated in the oncology space, according to a report released by data analysis firm IQVIA [1].
How biosimilar competition in Europe is changing
A report carried out at the request of the European Commission found that the development of access to biologicals in Europe remains challenging [1].
Developing access to biologicals remains challenging
In a report, carried out at the request of the European Commission, data analysis firm IQVIA, found that the development of access to biologicals in Europe remains challenging [1].
Savings from biosimilars reached an all-time high in 2021
A recent report has highlighted how despite the impact of the COVID-19 pandemic in 2020, the volume of biosimilar prescribing has generated a record high in savings from biosimilar competition.
Comparison of the cost of development of biologicals and biosimilars
The high cost of pharmaceuticals, in the case of biologicals, has a growing impact on healthcare costs worldwide.
Impact of COVID-19 pandemic on biologicals
A report released by data analysis firm IQVIA found that the COVID-19 pandemic has impacted certain segments of the biologicals market, but that, at least in Europe, this has not delayed the approval of new biosimilars [1].
Impact of biosimilar competition in Europe in 2021
A study of 23 European biosimilar markets has found that biologicals are an increasingly important component of pharmaceutical expenditure, due to their efficacy as treatments for complex conditions.
Market outlook for biological medicines in Brazil 2016‒2025
In a report on the role of biosimilars in health care by Professor Dr Claudio Tafla of the University of São Paulo studied the market growth outlook from 2016 to 2025 for biological medicines. Biological medicines currently represent the pharmaceutical industry's largest source of innovation.
